Solid phase synthesis of selective caspase-3 peptide inhibitors.
A robust method for the solid phase synthesis of a series of selective caspase-3 peptide inhibitors is described. The inhibitors can be obtained after cleavage from the solid support without further purification.
Merck Frosst Centre for Therapeutic Research, Merck Frosst Canada & Co. PO Box 1005, Pointe-Claire-Dorval, Québec, Canada H9R 4P8. erich_grimm@merck.com
Erich L
EL
Grimm
Bruno
B
Roy
Renee
R
Aspiotis
Christopher I
CI
Bayly
Donald W
DW
Nicholson
Dita M
DM
Rasper
Johanne
J
Renaud
Sophie
S
Roy
John
J
Tam
Paul
P
Tawa
John P
JP
Vaillancourt
Steven
S
Xanthoudakis
Robert J
RJ
Zamboni
D053148:Caspase 3; D061945:Caspase Inhibitors; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D020650:Combinatorial Chemistry Techniques; D004791:Enzyme Inhibitors / Q000138:chemical synthesis / Q000494:pharmacology; D006801:Humans; D020128:Inhibitory Concentration 50; D009842:Oligopeptides / Q000138:chemical synthesis* / Q000494:pharmacology*
D061945:Caspase Inhibitors; D004791:Enzyme Inhibitors; D009842:Oligopeptides; C505407:CASP3 protein, human; D053148:Caspase 3